Acropolis Investment Management LLC Sells 495 Shares of iShares Biotechnology ETF (NASDAQ:IBB)

Acropolis Investment Management LLC decreased its position in iShares Biotechnology ETF (NASDAQ:IBBFree Report) by 5.9% during the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 7,843 shares of the financial services provider’s stock after selling 495 shares during the period. Acropolis Investment Management LLC’s holdings in iShares Biotechnology ETF were worth $1,142,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Williams Financial LLC purchased a new stake in iShares Biotechnology ETF in the 2nd quarter worth approximately $867,000. PVG Asset Management Corp purchased a new stake in iShares Biotechnology ETF in the second quarter worth $415,000. Huntington National Bank boosted its holdings in iShares Biotechnology ETF by 17.9% in the third quarter. Huntington National Bank now owns 1,054 shares of the financial services provider’s stock valued at $153,000 after acquiring an additional 160 shares in the last quarter. Concourse Financial Group Securities Inc. increased its position in iShares Biotechnology ETF by 22.4% during the 2nd quarter. Concourse Financial Group Securities Inc. now owns 656 shares of the financial services provider’s stock valued at $90,000 after purchasing an additional 120 shares during the period. Finally, Raymond James & Associates raised its holdings in iShares Biotechnology ETF by 4.4% in the 2nd quarter. Raymond James & Associates now owns 189,766 shares of the financial services provider’s stock worth $26,047,000 after purchasing an additional 7,931 shares in the last quarter. 62.45% of the stock is currently owned by institutional investors.

iShares Biotechnology ETF Stock Down 0.0 %

Shares of IBB opened at $141.55 on Friday. iShares Biotechnology ETF has a 1-year low of $119.95 and a 1-year high of $150.57. The firm’s 50-day moving average price is $142.84 and its 200-day moving average price is $141.96.

iShares Biotechnology ETF Dividend Announcement

The company also recently announced a dividend, which was paid on Monday, September 30th. Shareholders of record on Wednesday, September 25th were issued a dividend of $0.2005 per share. The ex-dividend date of this dividend was Wednesday, September 25th.

iShares Biotechnology ETF Profile

(Free Report)

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.

Read More

Want to see what other hedge funds are holding IBB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares Biotechnology ETF (NASDAQ:IBBFree Report).

Institutional Ownership by Quarter for iShares Biotechnology ETF (NASDAQ:IBB)

Receive News & Ratings for iShares Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.